By Market Intelligence Team

Mindset Pharma Inc. (Mindset), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that, under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions (InterVivo), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across lysergic acid diethylamide (LSD), psilocybin, and o-methyl-bufotenin (5-MeO-DMT). The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!